The National Institutes of Health launched Bio Genesis Mission to use artificial intelligence to accelerate biomedical research, framed as an effort nested inside Genesis Mission created under a White House initiative. The program is set to draw on more than 15 federal agencies for awards, datasets, research facilities, and infrastructure. The White House said the initiative includes more than $5 billion in federal funds, with NIH allocating at least $1.2 billion in obligated FY 2026 funding and planned FY 2027 funding for areas including scaling biological manufacturing and accelerating drug development. NIH director Jay Bhattacharya said new funding opportunities will follow, while the cross-agency plan includes data infrastructure that brings together molecular, genomic, phenotypic, clinical, and real-world datasets to identify new uses for existing drugs and accelerate novel therapy translation. Bio Genesis Mission’s selection of challenge areas aligns directly with translational bottlenecks—biomanufacturing scale, drug discovery and chronic disease mechanisms—where AI and data integration are expected to move the fastest.